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Introduction
Breast density is one of the strongest independent predic-
tors of breast cancer risk [1–5], and the extent of breast
densities measured on a mammogram is correlated with a
woman’s menopausal status [6,7]. Premenopausal women
have a considerably larger proportion of dense breast
tissue than postmenopausal women, and in some women,
breast density is greater during the luteal phase of the
menstrual cycle when breast tissue is highly exposed to
estradiol and progesterone [8]. Reducing circulating
steroid hormone levels with a gonadotropin releasing
hormone agonist [9,10], or antagonizing effects of estro-
gens on breast tissue with tamoxifen [11], result in sub-
stantial reductions in breast density. Exogenous steroid
hormones have also been shown to influence breast
density, and recent studies provide evidence that post-
menopausal hormone replacement therapy (HRT) com-
posed of an estrogen plus a progestin (estrogen plus
CARE study = National Institute of Child Health and Human Development Women’s Contraceptive and Reproductive Experiences study; COMT =
catechol-O-methyltransferase gene; CYP17 = cytochrome p450c17α gene; EPRT = estrogen plus progestin replacement therapy; ERT = estrogen
replacement therapy; HRT = hormone replacement therapy; HSD3B1 = 3β-hydroxysteroid dehydrogenase type I gene; HSD17B1 = 17β-hydroxy-
steroid dehydrogenase type I gene; SD = standard deviation.
Available online http://breast-cancer-research.com/content/4/3/R5
Abstract
Background: Changes in breast density are highly correlated with steroid hormone exposure.
Materials and methods: In a cross-sectional study of 396 Caucasian and African-American women,
we evaluated whether polymorphisms in genes involved in steroid hormone biosynthesis and
metabolism, CYP17 (T27C), COMT (Val158Met), 17HSDB1 (Ser312Gly) and 3HSDB1
(Asn367Thr), predict mammographic density. We also evaluated whether associations vary by
menopausal and hormone replacement therapy status.
Results: We found no strong consistent relationships between polymorphisms in these genes and
breast density. African-American women homozygous for the Thr allele of 3HSDB1 had increased
density (the absolute difference versus the Asn/Asn genotype was +19.7%; P trend = 0.02), while
Caucasian homozygous women had decreased density (–5.1%; P trend = 0.04). Among
premenopausal women, carriers of the Ser allele had (not significantly) greater density (versus Gly/Gly
genotype: +7.1%; P trend = 0.07). In addition, among current users of hormone replacement therapy,
we observed that women with the low-activity Met/Met genotype of COMT had greater breast density
(versus the Val/Val genotype: +11.7%; P trend = 0.01).
Conclusion: Additional large studies evaluating these and other candidate breast cancer genes will be
required to determine what proportion, if any, of the interindividual differences in breast density are due
to underlying genetic variation in genes involved in steroid hormone biosynthesis or metabolism.
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progestin replacement therapy [EPRT]) increases breast
density to a much greater extent than postmenopausal
estrogen replacement therapy (ERT) alone [12,13].
Based on the epidemiologic evidence linking steroid hor-
mones with changes in breast density, we decided to
examine whether variation in genes that regulate steroid
hormone biosynthesis (CYP17, HSD17B1, HSD3B1)
and metabolism (COMT) may partially explain interindivid-
ual differences in mammographic density. Polymorphisms
in these genes have been proposed to represent biomark-
ers of long-term exposure to endogenous steroid hor-
mones and potential risk factors for breast cancer
[14–16]. We assessed the association between polymor-
phisms in these candidate genes and mammographic
density in a cross-sectional study of African-American and
Caucasian women who were part of a national, multi-
center, population-based, case-control study of breast
cancer. We also evaluated whether associations between
variant alleles of these genes and breast density differed
by menopausal status and HRT use.
Materials and methods
Women in this study were African-American and Cau-
casian breast cancer patients who participated in the
National Institute of Child Health and Human Development
Women’s Contraceptive and Reproductive Experiences
(CARE) study, which is a multicenter, population-based,
case-control study designed to evaluate risk factors for
breast cancer [17]. US-born African-American and Cau-
casian women, aged from 35 to 64 years, were eligible to
participate in the CARE study. Participants were enrolled
between July 1994 and April 1998, and were interviewed
in person using a standardized questionnaire to collect
detailed demographic information as well as information
regarding established and suspected breast cancer risk
factors, including oral contraceptive use, HRT use, family
history of breast cancer, age at menarche, number of
pregnancies, physical activity, and mammogram history
(for the five years preceding a reference date, which was
the date of diagnosis for patients). Breast cancer patients
participating in the CARE study in Los Angeles County
were identified by the Los Angeles County Cancer Surveil-
lance Program, which is a Surveillance, Epidemiology and
End Results registry program. These women were eligible
to be in the Radiographic Densities and Breast Cancer
Prevention study at the University of Southern California if
they had undergone a mammogram within five years of
their breast cancer diagnosis. The Radiographic Densities
study was designed to examine the association between
mammographic densities and breast cancer risk. As part
of this study, mammograms of the contralateral (cancer
free) breast were obtained from 242 African-American and
312 Caucasian breast cancer cases (73% of the total eli-
gible African-American and Caucasian cases in the Los
Angeles section of the CARE study, n = 755). Of these,
blood samples had been collected as part of the CARE
Study from 436 of the 554 (78.7%) women for whom we
obtained a mammogram. The study protocol was
approved by the Institutional Review Board at the Univer-
sity of Southern California.
Mammographic density assessment
Mammograms were digitized using a Cobrascan CX312.T
scanner (Radiographic Digital Imaging, Compton, CA,
USA). All assessments were done using a computer-
assisted method on the digitized cranio-caudal mammo-
graphic image that we have previously described and
validated [10]. The mammographic image is first digitized
and displayed on the computer screen. Next, the reader
outlines the breast and the software calculates the total
area of the breast. The reader then uses a tinting tool to
apply a yellow tint to gray levels within the breast above
the threshold X, where all pixels equal to or greater than X
are considered to represent mammographic densities. The
reader excludes artefactual dense areas such as the pec-
toralis muscle, prominent veins, and fibrous strands. The
software counts the number of tinted pixels within the
defined breast area. The percentage of the breast area
with densities is taken as the ratio of the tinted area within
the region of interest : total area of the breast (×100). This
breast density assessment method has been found to be
highly reproducible and correlates well with the subjective
classification method [10]. A subset of the mammograms in
this study were interpreted by an expert reader (IMS). The
correlation between these expert readings and the com-
puter-assisted readings was 0.90. A subset of the readings
were reread blindly with the computer-assisted method, and
correlation between these readings was also 0.90.
Genotyping analysis
DNA was extracted from buffy coat fractions using the
Qiagen Blood DNA Extraction Kit (Qiagen, Valencia, CA,
USA). We genotyped one polymorphism in the tran-
scribed, but untranslated, region of CYP17 (T27C; alleles
A1, A2, respectively), and missense polymorphisms in
COMT (Val158Met), 17HSDB1 (Ser312Gly), and
3HSDB1 (Asn367Thr). All genotyping was performed by
the Taqman Allelic Discrimination Method [18]. Reaction
conditions, primers and probes are available from the cor-
responding author.
Statistical analysis
Generalized linear models were used to estimate least-
squares arithmetic and geometric mean percentages of
breast density for each genotype. Both arithmetic and log-
transformed percentages gave similar results and the
arithmetic means are provided. We also report the
absolute differences in percent breast density between
genotypes. Gene dosage was evaluated by including
genotype as an ordinal variable in multivariate models. We
adjusted for the following predictors of breast density:
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1 Age at mammogram (years): <40; 40–44; 45–49;
50–54; 55–59; >59.
2 Body mass index (kg/m2): <22; 22–24.9; 25–29.9; ≥30.
3 Age at menarche (years): <12; 12; 13; >13.
4 Parity (children)/age at first birth (years): nulliparous;
1–2/< 24; 1–2/≥24; ≥3<24; ≥3/≥24.
5 First degree family history of breast cancer: yes; no;
not known.
6 Menopausal status/HRT use status at mammography:
premenopausal; postmenopausal/never used HRT or
past HRT user; postmenopausal/current ERT user;
postmenopausal/current EPRT user; unknown status.
7 Race: African-American; Caucasian.
We also evaluated associations between genotype and
mammographic density by menopausal and HRT status.
Interactions between genotype and HRT status were eval-
uated by including multiplicative interaction terms between
HRT status (past user or never used versus current user)
and genotype (ordinal). Data were analyzed using SAS
software [19].
Results
A total of 152 African-American and 244 Caucasian
women, with mean ages at the time of their mammogram
of 48.4 years (standard deviation [SD] 7.7) and 48.2 years
(SD 8.9), respectively, participated in the study. The
average duration between the mammogram and breast
cancer diagnosis was 5.7 months (range 0–63 months).
After adjustment for body mass index, differences in mam-
mographic density did not differ between African-Ameri-
can and Caucasian women (Table 1). The percentage of
breast density among current users of ERT or EPRT (HRT
users) was slightly greater than that of premenopausal
women, while density was substantially lower among
women with no HRT use. Associations between percent
breast density and established breast cancer risk factors
were in the expected directions, except for age at menar-
che where breast density was significantly greater for
women with a later age at menarche (P = 0.04).
CYP17 genotype was not a strong predictor of breast
density among African-American or Caucasian women
(Table 2). The direction and magnitude of the associations
between COMT, 17HSDB1, and 3HSDB1 genotypes,
and breast density, were not consistent for African-Ameri-
can and Caucasian women. African-American women
homozygous for the low-activity allele (Met) of COMT had
greater breast density (the absolute difference compared
to the Val/Val genotype was +5.4% density); however, a
significant gene-dosage effect was not observed
(P trend = 0.19). This modest association with COMT
genotype was not observed among Caucasian women.
Among Caucasian women, carriers of the Ser allele of
17HSDB1 had greater breast density (Ser/Ser versus
Gly/Gly genotype: +4.1% density), while the Thr allele of
3HSDB1 was associated with lower breast density
(Thr/Thr versus Asn/Asn genotype: –5.1% density).
Among African-Americans, the Thr allele was less
common (prevalence, 15%), and women homozygous for
this allele had greater breast density (versus Asn/Asn
genotype: +19.7% density).
Among premenopausal women, carriers of the Ser allele
had (not significantly) greater density (versus the Gly/Gly
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Table 1
Mean percentage of breast density by descriptive
characteristics (n = 396)
Mean
Characteristic n (%) % density P§
Race*
African-American 152 (38) 34.8
Whites 244 (68) 34.8 0.98
Menopausal status/ HRT use**,†
Premenopausal 176 (44) 35.4
Postmenopausal
Never used or past user 67 (17) 30.4
of HRT
Current user of ERT 53 (13) 39.3
Current user of EPRT 51 (13) 39.8 0.08
Age at mammogram (years)
≤40 91 (23) 45.6
41–45 84 (21) 41.2
46–50 41 (10) 38.3
51–55 74 (19) 34.4
56–60 69 (17) 28.3
>60 37 (9) 28.9 <0.0001
Body mass index (kg/m2)**
<22 114 (29) 49.8
22–24.9 107 (27) 38.3
25–29.9 111 (28) 29.2
≥30 64 (16) 21.8 <0.0001
Parity**
0 83 (21) 45.1
1–2 175 (44) 38.0
3+ 138 (35) 29.1 <0.0001
Age at first birth (years)**
<25 191(61) 30.9
25–30 69 (22) 35.1
≥30 53 (17) 43.8 0.0004
Age at menarche (years)**
<12 106 (27) 32.6
12 105 (27) 36.5
13 97 (24) 34.7
>13 88 (22) 41.3 0.04
First-degree family history of breast cancer**,‡
No 256 (65) 35.0
Yes 120 (30) 39.3 0.12
*Adjusted for age and body mass index. **Adjusted for age. †n = 49
missing menopausal/ hormone replacement therapy (HRT) status.
‡n = 20 missing family history information. §Analysis of covariance.
EPRT, estrogen plus progestin replacement therapy; ERT, estrogen
replacement therapy.
genotype: +7.1%; P trend = 0.07) (Table 3). We observed
little evidence of a relationship between CYP17, COMT,
or 3HSDB1 genotypes, and breast density among pre-
menopausal women. For postmenopausal women, we did
observe suggestive evidence that the direction of the
associations between CYP17 and COMT genotypes, and
breast density differed by HRT status (for interactions,
P = 0.13 and P = 0.10, respectively). Among current HRT
users, women with A2/A2 genotype of CYP17 had
greater density (versus A1/A1 genotype: +10.7%
density), while in the group of women who either had
never used HRT or were past users, those with the A2/A2
genotype had lower density (versus A1/A1 genotype:
–7.0% density). In analyses among current HRT users,
women with the Met/Met COMT genotype had greater
breast density (versus Val/Val genotype: +11.7% density;
P trend = 0.01). We had limited power to assess associa-
tions among the women who either had never used HRT
or were past users, due to the small number of post-
menopausal women in this study who were not currently
using HRT.
Discussion
CYP17, 17HSDB1 and 3HSDB1 encode key enzymes
involved in steroid hormone biosynthesis, and common
polymorphisms in these genes may account for part of the
observed interindividual variation in mammographic
density. The single nucleotide polymorphism (T → C) in
the 5′-transcribed but untranslated region of CYP17 has
been studied extensively in relation to breast cancer risk
(for review, see [20]). Most, but not all of these studies,
have been null. However, some data suggest that women
with the A2/A2 genotype have modestly higher levels of
circulating estrogens [21,22]. In another study of genetic
variation in relation to mammographic density among Cau-
casian women (n = 538; Haiman et al., unpublished
observations), CYP17 genotype was not a strong predic-
tor of breast density. The results from our study are com-
patible with studies suggesting that this polymorphism is
not a strong breast cancer risk factor. Two studies have
examined the Ser312Gly polymorphism in exon 6 of
17HSDB1 in relation to breast cancer risk and both
reported a positive association with the Ser allele [14,23].
Although we found slightly greater density among Cau-
casian women with the Ser/Ser genotype, this result was
not statistically significant. It is currently not known
whether the missense variant (Asn367Thr [24]) in exon 4
of 3HSDB1 alters the normal activity of the enzyme,
Breast Cancer Research    Vol 4 No 3 Haiman et al.
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Table 2
Least-squares mean percentage breast density by genotype
Genotype All women* Caucasians** African-Americans**
mean (n) mean (n) mean (n)
CYP17
A1/A1 34.1 (144) 33.7 (87) 34.6 (57)
A1/A2 34.8 (204) 34.6 (127) 35.0 (77)
A2/A2 37.2 (48) 39.1 (30) 34.6 (18)
P trend 0.40 0.26 0.95
COMT
Val/Val 33.4 (139) 34.3 (76) 32.3 (63)
Val/Met 35.8 (175) 35.6 (104) 36.2 (71)
Met/Met 34.9 (82) 34.2 (64) 37.7 (18)
P trend 0.46 0.99 0.19
17HSDB1
Gly/Gly 32.4 (109) 32.0 (71) 33.3 (38)
Gly/Ser 35.8 (191) 35.9 (121) 35.6 (70)
Ser/Ser 35.6 (96) 36.1 (52) 34.9 (44)
P trend 0.24 0.22 0.73
3HSDB1
Asn/Asn 35.4 (240) 37.4 (131) 32.9 (109)
Asn/Thr 33.6 (126) 31.5 (88) 38.4 (38)
Thr/Thr 35.1 (27) 32.3 (23) 52.6 (4)
P trend 0.58 0.04 0.02
*Adjusted for race, age, body mass index (BMI), menopausal status/
hormone replacement therapy (HRT) use, parity, age at first birth, age
at menarche and first-degree family of breast cancer. **Adjusted for
age, BMI, menopausal status/HRT use, parity, age at first birth, age at
menarche and first-degree family of breast cancer.
Table 3
Least-squares mean percentage breast density by menopausal
and HRT status
Postmenopausal/HRT status*
Premeno- Never and Current
pausal* past use use**
Genotype mean (n) mean (n) mean (n) P***
CYP17
A1/A1 34.0 (58) 31.9 (26) 37.9 (39)
A1/A2 35.7 (94) 30.5 (33) 38.6 (52)
A2/A2 37.9 (24) 24.9 (8) 48.6 (13)
P trend 0.39 0.42 0.16 0.13
COMT
Val/Val 36.9 (62) 29.7 (20) 33.7 (39)
Val/Met 34.4 (70) 31.6 (40) 42.3 (46)
Met/Met 34.9 (44) 25.3 (7) 45.4 (19)
P trend 0.56 0.80 0.01 0.10
17HSDB1
Gly/Gly 32.0 (52) 24.0 (13) 41.1 (32)
Gly/Ser 35.5 (76) 33.7 (40) 39.4 (47)
Ser/Ser 39.1 (48) 26.9 (14) 38.2 (25)
P trend 0.07 0.77 0.57 0.65
3HSDB1
Asn/Asn 35.5 (106) 32.8 (42) 40.6 (61)
Asn/Thr 33.4 (56) 25.8 (23) 40.8 (32)
Thr/Thr 42.7 (14) 31.8 (2) 28.9 (9)
P trend 0.55 0.27 0.22 0.95
*Adjusted for race, age, body mass index, parity, age at first birth, age
at menarche and first-degree family history of breast cancer. **Current
use of estrogen replacement therapy or estrogen plus progestin
replacement therapy. ***P value for interaction between hormone
replacement therapy (HRT) status (never used and past use versus
current use) and genotype (ordinal).
steroid hormone levels, and breast cancer risk. Our finding
of higher density with the Thr allele in African-Americans is
based on small numbers (Thr/Thr genotype: n = 4) and
may be due to chance.
Catechol metabolites of estrogen (i.e. 2-OH and 4-OH
estrogens) have been demonstrated to have cancer-pro-
moting properties [25]. One route of catechol estrogen
inactivation is by O-methylation, which is catalyzed by the
enzyme catechol-O-methyltransferase (COMT). COMT
activity is polymorphic in humans and the missense variant
we evaluated (Met allele) has been associated with lower
enzymatic activity [26,27]. However, studies have been
inconsistent in linking the Met allele with breast cancer
risk [16,28–30]. In another study of genetic determinants
of mammographic density (Haiman et al., unpublished
observations), COMT genotypes were associated with
mammographic density, but the association went in the
opposite direction for premenopausal and post-
menopausal women. Premenopausal women homozygous
for the ‘low-activity’ Met allele of COMT had (not signifi-
cantly) greater breast density (Met/Met versus Val/Val
genotypes: +9.2% density; P = 0.18), while among post-
menopausal women who had never used or were past
users of HRT, the Met allele was associated with lower
density (Met/Met versus Val/Val genotypes: –5.3%
density; P = 0.04). In contrast, among postmenopausal
women in the present study who were current HRT users,
we observed carriers of the Met/Met genotype to have
greater density than those with the Val/Val genotype. Our
data support the observation that breast cancer risk asso-
ciated with the Met allele may be greater among long-term
HRT users [30].
The women evaluated in this study were originally
selected based on their diagnosis with breast cancer, and
thus, it is possible that the associations we observed may
not reflect associations among unaffected women in the
general population. The mammograms in our study were
collected, on average, only six months prior to diagnosis. It
is possible that invasive breast cancer alters breast
density in the contralateral breast prior to diagnosis;
however, among the women for whom we had collected
several mammograms at different times, there was little
indication that such a change took place. Although there
may have been some nondifferential misclassification of
the mammographic density readings that would have
biased the results towards the null, we think any such mis-
classification is likely to have been minimal, given the high
correlations between duplicate blinded readings and the
high correlation between the readings used and those of
an expert reader.
Conclusion
In conclusion, in this study we did not observe compelling
evidence of an association between variant alleles of
CYP17, COMT, 17HSDB1 and 3HSDB1 and breast
density. Modest associations between these genes and
breast cancer risk have been hypothesized (relative risks
approximately 1.2–1.5), however, conclusive data linking
any of the four variants we examined with breast cancer
risk are lacking. If these variants do have a moderate bio-
logical effect on steroid hormone biosynthesis or metabo-
lism, then the genotype differences in percent
mammographic density we are attempting to discern are
most likely to be small. Additional data from large mammo-
graphic density and breast cancer studies of these and
other candidate genes are required before we can accu-
rately assess the impact of these allelic variants.
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